GlaxoSmithKline PLC
XHAM:GS7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GlaxoSmithKline PLC
XHAM:GS7
|
UK |
|
C
|
Cheniere Energy Inc
XMUN:CHQ1
|
US |
|
Vivendi SE
OTC:VIVEF
|
FR |
|
Geely Automobile Holdings Ltd
HKEX:175
|
HK |
|
Brainchip Holdings Ltd
F:24Y
|
AU |
|
N
|
Newcrest Mining Ltd
F:NMA
|
AU |
|
P
|
Perk Labs Inc
OTC:PKLBF
|
CA |
|
J
|
J Taparia Projects Ltd
BSE:538539
|
IN |
Wall St Price Targets
GS7 Price Targets Summary
GlaxoSmithKline PLC
According to Wall Street analysts, the average 1-year price target for GS7 is 17.012 EUR with a low forecast of 11.892 EUR and a high forecast of 23.367 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GS7's stock price target?
Price Target
17.012
EUR
According to Wall Street analysts, the average 1-year price target for GS7 is 17.012 EUR with a low forecast of 11.892 EUR and a high forecast of 23.367 EUR.
What is the Revenue forecast for GlaxoSmithKline PLC?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 3%.
What is the Operating Income forecast for GlaxoSmithKline PLC?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 3%.
What is the Net Income forecast for GlaxoSmithKline PLC?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 8 years is 4%.
